Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 2
---
January 17, 2025, Biodexa Pharmaceuticals Plc (the “Company”) entered into a securities purchase agreement (the “Purchase
Agreement”) with C/M Capital Master Fund, LP (the “Purchaser”), pursuant to which the Company, subject to the restrictions
and satisfaction of the conditions in the Purchase Agreement, has the right, but not the obligation, to sell to the Purchaser, and the
Purchaser is obligated to purchase, up to $35 million of newly issued shares (the “Purchase Shares”) of the Company’s
American Depositary Shares (the “Depositary Shares”), each representing 10,000 of the Company’s ordinary shares, nominal
value £0.00005 each (the “Ordinary Shares”).

As consideration
for the Purchaser’s execution and delivery of the Purchase Agreement, the Company has agreed to pay to the Purchaser a fee of $875,000
in cash (the “Commitment Fee”), of which (i) $612,500 shall be paid to the Purchaser concurrently with the execution of the
Purchase Agreement and (ii) the balance of such Commitment Fee shall be paid to the Purchaser, in a pro rata fashion, simultaneously with
the delivery of any Purchase Shares under the Purchase Agreement (each, a “Commitment Fee Payment Date”). If the Company were
to fail to pay the applicable portion of the Commitment Fee to the Purchaser on the applicable Commitment Fee Payment Date, the Company
has the right, in its sole discretion, to issue Depositary Shares representing the value of the applicable portion of the Commitment Fee
(the “Commitment Shares,” and together with the Purchase Shares, the “Securities”) to release the Company of its
liability to pay the Commitment Fee, valued at the closing sale price of the Depositary Shares on the trading day immediately prior to
the date of the Purchase Agreement.

The
Company does not have a right to commence any sales of Depositary Shares to the Purchaser under the Purchase Agreement until the time
when all of the conditions to the Company’s right to commence sales of Depositary Shares to the Purchaser set forth in the Purchase
Agreement have been satisfied, including that a registration statement covering the resale of the Securities is declared effective by
the United States Securities and Exchange Commission (the “SEC”) and the final form of prospectus contained therein is filed
with the SEC (the “Commencement Date”).

Over
the